<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age/><report-id>PHHY2012JP109912</report-id><gender>male</gender><reactions><reaction>Osteonecrosis of jaw</reaction><reaction>Mandibular osteomyelitis</reaction><reaction>Mandibular exposure</reaction><reaction>Elevated lesion appeared in the mandible</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>ZOLEDRONIC ACID</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CHEMOTHERAPEUTICS</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>DEXAMETHASONE</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Metastases to bone</indication></indications><outcomes/><country>Japan</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053204_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134638</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHY2012JP109912</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-11-26</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-07</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012JP109912</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportergivename>Iida</reportergivename>
			<reporterfamilyname>Hiroaki</reporterfamilyname>
			<reporterorganization>Toyama University</reporterorganization>
			<reportercity>Toyama Prefecture</reportercity>
			<reportercountry>JP</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
			<literaturereference>Hiroaki I, Asao Y, Ito T, Morii A, Yasuda K, Watabe A, Nozaki T, Fujiuchi Y, Komiya A, Fuse H, Higuchi K, Tsuno H.. A Case of Castration-Resistant Prostate Cancer Complicated by Osteonecrosis of the jaw. 2012;58 (10):589</literaturereference>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientagegroup>6</patientagegroup>
			<patientsex code="1">Male</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Prostate cancer</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Prostatic specific antigen increased</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>1997</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
				<patientmedicalcomment>4.09 ng/ml</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Biopsy prostate</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>199712</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
				<patientmedicalcomment>Diagnosis of prostate cancer.</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Prostatectomy</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>199807</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
				<patientmedicalcomment>Postoperatively, hormone therapy was continued.</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Radioisotope scan</patientepisodename>
				<patientmedicalcomment>Bone scintigraphy reveled metastasis to the right pubic bone. So, chemotherapy was started</patientmedicalcomment>
			</medicalhistoryepisode>
			<patientpastdrugtherapy>
				<patientdrugname>HORMONES</patientdrugname>
			</patientpastdrugtherapy>
			<reaction>
				<primarysourcereaction>Osteonecrosis of jaw</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Osteonecrosis of jaw</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Osteonecrosis of jaw</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Mandibular osteomyelitis</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Osteomyelitis of jaw</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Osteomyelitis</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Mandibular exposure</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Exposed bone in jaw</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Exposed bone in jaw</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Elevated lesion appeared in the mandible</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Bone lesion</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Bone lesion</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ZOLEDRONIC ACID</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationnumb>21-223</drugauthorizationnumb>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugdosageform normalized="solution for infusion">Solution For Infusion</drugdosageform>
				<drugadministrationroute code="041">Intravenous drip</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Metastases to bone</drugindication>
				<drugstartdateformat>602</drugstartdateformat>
				<drugstartdate>2008</drugstartdate>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ZOLEDRONATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Bone lesion</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Bone lesion</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Exposed bone in jaw</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Exposed bone in jaw</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Osteomyelitis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Osteomyelitis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Osteonecrosis of jaw</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Osteonecrosis of jaw</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>CHEMOTHERAPEUTICS</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugenddateformat>610</drugenddateformat>
				<drugenddate>2011-08-01</drugenddate>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>NO INGREDIENTS/SUBSTANCES</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>DEXAMETHASONE</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>DEXAMETHASONE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012JP109912, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>literature report received from a <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">health care professional </Semaphore>(author) on 26 Nov 2012 with follow up report received from a <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">health care professional </Semaphore>(author) on 07 Dec 2012. The author discussed about a case <Semaphore x="2430024" class="Disease or Finding" value="Prostate Carcinoma" score="1.00" ID="C4863">of <Semaphore x="2339358" class="Procedure" value="Orchiectomy" score="1.00" ID="C15288">castration </Semaphore><Semaphore x="2456266" class="Disease or Finding" value="Refractory Carcinoma" score="1.00" ID="C8511">resistant <Semaphore x="2429227" class="Disease or Finding" value="Prostate Carcinoma by AJCC v6 Stage" score="1.00" ID="C90521">prostate cancer </Semaphore></Semaphore></Semaphore>complicated by <Semaphore x="2351521" class="Disease or Finding" value="Osteonecrosis of Jaw" score="1.00" ID="C63924">osteonecrosis of the jaw</Semaphore>. This report refers to an approximately 70-year old male patient. During the health <Semaphore x="1759538" class="Procedure" value="Checkup" score="1.00" ID="C41383">checkup </Semaphore>in 1997, the patient was found to have elevation in <Semaphore x="2432387" class="Procedure" value="Prostate Specific Antigen Measurement" score="1.00" ID="C17634">PSA </Semaphore><Semaphore x="779631" class="Medicine" value="Level" score="0.49" ID="187620">level </Semaphore>(4.09 ng/ml). In Dec 1997, he visited the department, where <Semaphore x="1593625" class="Procedure" value="Biopsy of Prostate" score="1.00" ID="C51701">prostate biopsy </Semaphore>was carried out and a <Semaphore x="1673355" class="Procedure" value="Cancer Diagnosis" score="1.00" ID="C16213">diagnosis <Semaphore x="2430024" class="Disease or Finding" value="Prostate Carcinoma" score="1.00" ID="C4863">of <Semaphore x="2429227" class="Disease or Finding" value="Prostate Carcinoma by AJCC v6 Stage" score="1.00" ID="C90521">prostate cancer </Semaphore></Semaphore></Semaphore>was <Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">made</Semaphore>. <Semaphore x="1884852" class="Procedure" value="Endocrine Therapy" score="1.00" ID="C15445"><Semaphore x="2032177" class="Disease or Finding" value="Hormone-Resistant Breast Cancer" score="1.00" ID="C114932">Hormone </Semaphore>therapy </Semaphore>was started and total <Semaphore x="2432534" class="Procedure" value="Prostatectomy" score="1.00" ID="C15307">prostatectomy </Semaphore>was carried out in Jul 1998. Postoperatively, <Semaphore x="1884852" class="Procedure" value="Endocrine Therapy" score="1.00" ID="C15445"><Semaphore x="2032177" class="Disease or Finding" value="Hormone-Resistant Breast Cancer" score="1.00" ID="C114932">hormone </Semaphore>therapy </Semaphore>was continued. In Sep 2004, <Semaphore x="2432387" class="Procedure" value="Prostate Specific Antigen Measurement" score="1.00" ID="C17634">PSA </Semaphore>raised to 14 ng/ml. <Semaphore x="3107233" class="MedDRA LLT" value="Metastases to bone" score="1.00" ID="10027452"><Semaphore x="2222549" class="Disease or Finding" value="Metastatic Malignant Neoplasm to the Bone" score="1.00" ID="C3580"><Semaphore x="1619584" class="AnatomicStructure" value="Bone" score="1.00" ID="C12366">Bone </Semaphore><Semaphore x="3219368" class="MedDRA LLT" value="Radioisotope scan" score="1.00" ID="10061478">scintigraphy </Semaphore>reveled <Semaphore x="3108419" class="MedDRA LLT" value="Metastasis" score="1.00" ID="10062194">metastasis </Semaphore></Semaphore>to </Semaphore>the right <Semaphore x="2438086" class="AnatomicStructure" value="Pubic Bone" score="1.00" ID="C33423">pubic <Semaphore x="1619584" class="AnatomicStructure" value="Bone" score="1.00" ID="C12366">bone</Semaphore></Semaphore>. So, <Semaphore x="1760803" class="Procedure" value="Chemotherapy" score="1.00" ID="C15632">chemotherapy </Semaphore>was started. The patient received <Semaphore x="1384774" class="Medicine" value="zoledronic acid" score="0.74" ID="274011">zoledronic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid </Semaphore></Semaphore>(<Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer </Semaphore>unknown) for <Semaphore x="2429227" class="Disease or Finding" value="Prostate Carcinoma by AJCC v6 Stage" score="1.00" ID="C90521">prostate cancer </Semaphore>from 2008 (unknown date) and at an unspecified dose. In Aug 2011, <Semaphore x="1760803" class="Procedure" value="Chemotherapy" score="1.00" ID="C15632">chemotherapy </Semaphore>was discontinued and <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral </Semaphore><Semaphore x="447349" class="Medicine" value="Dexamethasone" score="0.49" ID="253106">dexamethasone </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>was started. In those days, an elevated <Semaphore x="2107425" class="Disease or Finding" value="Lesion" score="1.00" ID="C3824">lesion </Semaphore>appeared in the <Semaphore x="2199108" class="AnatomicStructure" value="Mandible" score="1.00" ID="C12290">mandible</Semaphore>. On the <Semaphore x="187403" class="Medicine" value="Basis" score="0.49" ID="189629">basis </Semaphore>of consultation with the departments of <Semaphore x="2352967" class="AnatomicStructure" value="Otolith" score="1.00" ID="C33230">otorhinolaryngology </Semaphore>and dentistry/oral <Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">surgery </Semaphore>and the findings of <Semaphore x="2199076" class="Disease or Finding" value="Mandible Fracture" score="1.00" ID="C26824">mandibular </Semaphore><Semaphore x="2351505" class="Disease or Finding" value="Osteomyelitis" score="1.00" ID="C27577">osteomyelitis </Semaphore>and <Semaphore x="2199076" class="Disease or Finding" value="Mandible Fracture" score="1.00" ID="C26824">mandibular </Semaphore>exposure, the patient was <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosed </Semaphore>as having <Semaphore x="2351521" class="Disease or Finding" value="Osteonecrosis of Jaw" score="1.00" ID="C63924">osteonecrosis of the jaw</Semaphore>. <Semaphore x="1384774" class="Medicine" value="zoledronic acid" score="0.74" ID="274011">Zoledronic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid </Semaphore></Semaphore>was discontinued and <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral cavity </Semaphore>cleansing and <Semaphore x="1531928" class="Procedure" value="Antibiotic Therapy" score="1.00" ID="C15620"><Semaphore x="122820" class="Medicine" value="Antibiotic" score="0.49" ID="299081">antibiotic </Semaphore>therapy </Semaphore>were started. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event was unknown. The seriousness of the event was assessed as serious (medically significant). The causality of the event was not reported.Follow up report received on 07 Dec 2012: Added medical history, symptomatic events of <Semaphore x="2351521" class="Disease or Finding" value="Osteonecrosis of Jaw" score="1.00" ID="C63924">ONJ </Semaphore>(<Semaphore x="2199108" class="AnatomicStructure" value="Mandible" score="1.00" ID="C12290"><Semaphore x="1613776" class="Disease or Finding" value="Bone Lesion" score="1.00" ID="C43260"><Semaphore x="1619584" class="AnatomicStructure" value="Bone" score="1.00" ID="C12366">bone </Semaphore>lesion</Semaphore>, mandibular </Semaphore><Semaphore x="2351505" class="Disease or Finding" value="Osteomyelitis" score="1.00" ID="C27577">osteomyelitis </Semaphore>and <Semaphore x="2199076" class="Disease or Finding" value="Mandible Fracture" score="1.00" ID="C26824">mandibular </Semaphore>exposure).</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>